Quality of Life and Adherence to Treatment in Patients with Phenylketonuria in the Federal District - Brazil
Psicologia: Teoria e Pesquisa · 2026 · 42
DOI: 10.1590/0102.3772e42402.en ↗Kurz gefasst
Fachartikel in der Zeitschrift Psicologia: Teoria e Pesquisa, 2026. Verfasst von Adriana Haack und 1 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In phenylketonuria (PKU), low adherence to treatment is associated with poor health-related quality of life (HRQoL). The HRQoL of 51 patients with PKU was examined using the PKU-QOL questionnaires, correlating them to two indicators of adherence to treatment using nonparametric tests, according to the results of normality tests. Children, adolescents, and adults achieved adherence to treatment percentages of 62.5%, 63.6%, and 18.8%, respectively. Significant correlations between PKU-QOL scores were observed in several age groups, except in children, due to the reduced sample size (n=4). PKU negatively affects the HRQoL of patients and their caregivers. Improvements in dietary treatment, with the provision of manufactured special low-protein foods, more palatable Phe-free or low-Phe protein substitutes, and improved pharmacological therapies are necessary.
Zitieren
APA
Haack, A., & Poubel, M. (2026). Quality of Life and Adherence to Treatment in Patients with Phenylketonuria in the Federal District - Brazil. Psicologia: Teoria e Pesquisa, 42. https://doi.org/10.1590/0102.3772e42402.en
Vancouver
Haack A, Poubel M. Quality of Life and Adherence to Treatment in Patients with Phenylketonuria in the Federal District - Brazil. Psicologia: Teoria e Pesquisa. 2026;42. doi:10.1590/0102.3772e42402.en
BibTeX
@article{Haack2026,
author = {Haack, Adriana and Poubel, Monique},
title = {Quality of Life and Adherence to Treatment in Patients with Phenylketonuria in the Federal District - Brazil},
journal = {Psicologia: Teoria e Pesquisa},
year = {2026},
volume = {42},
doi = {10.1590/0102.3772e42402.en}
}
EUVIMED